Pharma Foods International Co., Ltd. (TYO:2929)
Japan · Delayed Price · Currency is JPY 657.00
-11.00 (-1.65%)
Feb 13, 2026, 3:30 PM JST
TYO:2929 Income Statement
Financials in millions JPY. Fiscal year is August - July.
Millions JPY. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
| 66,376 | 65,260 | 62,147 | 68,572 | 60,185 | 46,752 | |
Revenue Growth (YoY) | 9.53% | 5.01% | -9.37% | 13.94% | 28.73% | 204.51% |
Cost of Revenue | 13,064 | 12,676 | 13,395 | 13,293 | 12,077 | 7,027 |
Gross Profit | 53,312 | 52,584 | 48,752 | 55,279 | 48,108 | 39,725 |
Selling, General & Admin | 52,900 | 48,763 | 42,561 | 50,757 | 46,211 | 33,486 |
Research & Development | 1,394 | 1,399 | 978 | 840 | 766 | 522 |
Amortization of Goodwill & Intangibles | 43 | 53 | 99 | 72 | 51 | 43 |
Operating Expenses | 54,337 | 50,215 | 43,638 | 51,669 | 47,028 | 34,051 |
Operating Income | -1,025 | 2,369 | 5,114 | 3,610 | 1,080 | 5,674 |
Interest Expense | -92 | -91 | -62 | -48 | -26 | -12 |
Interest & Investment Income | 46 | 39 | 29 | 27 | 38 | 6 |
Earnings From Equity Investments | -81 | -131 | -35 | -82 | 5 | 16 |
Currency Exchange Gain (Loss) | -3 | -1 | 4 | 8 | 37 | 16 |
Other Non Operating Income (Expenses) | 175 | 367 | 198 | 76 | 130 | 66 |
EBT Excluding Unusual Items | -980 | 2,552 | 5,248 | 3,591 | 1,264 | 5,766 |
Gain (Loss) on Sale of Investments | -117 | -118 | -113 | -50 | 81 | - |
Gain (Loss) on Sale of Assets | 4 | - | - | -6 | 77 | - |
Asset Writedown | - | - | -101 | - | - | -1 |
Other Unusual Items | - | - | -1 | 8 | 1 | - |
Pretax Income | -1,093 | 2,434 | 5,033 | 3,543 | 1,423 | 5,765 |
Income Tax Expense | 790 | 2,066 | 1,828 | 462 | 1,797 | 1,924 |
Earnings From Continuing Operations | -1,883 | 368 | 3,205 | 3,081 | -374 | 3,841 |
Net Income | -1,883 | 368 | 3,205 | 3,081 | -374 | 3,841 |
Net Income to Common | -1,883 | 368 | 3,205 | 3,081 | -374 | 3,841 |
Net Income Growth | - | -88.52% | 4.03% | - | - | 456.67% |
Shares Outstanding (Basic) | 29 | 29 | 28 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 28 | 29 | 29 | 29 |
Shares Change (YoY) | 2.94% | 1.06% | -1.51% | -0.47% | -0.18% | 0.04% |
EPS (Basic) | -65.06 | 12.80 | 112.69 | 106.70 | -12.89 | 132.20 |
EPS (Diluted) | -65.06 | 12.80 | 112.69 | 106.70 | -12.89 | 132.14 |
EPS Growth | - | -88.64% | 5.62% | - | - | 456.13% |
Free Cash Flow | -4,133 | -1,983 | 4,645 | 5,739 | -6,532 | 5,784 |
Free Cash Flow Per Share | -143.17 | -68.99 | 163.32 | 198.74 | -225.13 | 198.99 |
Dividend Per Share | 25.000 | 25.000 | 25.000 | 22.000 | 20.000 | 20.000 |
Dividend Growth | - | - | 13.64% | 10.00% | - | 135.29% |
Gross Margin | - | 80.58% | 78.45% | 80.62% | 79.93% | 84.97% |
Operating Margin | -1.54% | 3.63% | 8.23% | 5.27% | 1.79% | 12.14% |
Profit Margin | -2.84% | 0.56% | 5.16% | 4.49% | -0.62% | 8.22% |
Free Cash Flow Margin | -6.23% | -3.04% | 7.47% | 8.37% | -10.85% | 12.37% |
EBITDA | -253 | 3,154 | 6,021 | 4,156 | 1,600 | 5,855 |
EBITDA Margin | - | 4.83% | 9.69% | 6.06% | 2.66% | 12.52% |
D&A For EBITDA | 772 | 785 | 907 | 546 | 520 | 181 |
EBIT | -1,025 | 2,369 | 5,114 | 3,610 | 1,080 | 5,674 |
EBIT Margin | - | 3.63% | 8.23% | 5.27% | 1.79% | 12.14% |
Effective Tax Rate | - | 84.88% | 36.32% | 13.04% | 126.28% | 33.37% |
Advertising Expenses | - | 36,692 | 30,787 | 38,865 | 35,748 | 24,860 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.